arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Lifevantage Corp

LFVN
$5.08 ▼ -0.84 (-14.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
68
Health
Good
Neutral
auto_awesome

Analytical Summary

Lifevantage Corp shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth -23.1% ↗
Op. Margin 3.9% ↗
ROIC 3.7% ↘
FCF / Share None
Trailing P/E 50.8x
Price / Book 1.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$42.38M
↓ -23.1% —
Net Income Profit after all expenses
$1.28M
↓ -34.7% —
Operating Margin Operating profit as % of sales
3.9%
↑ +2.5% 38th
FCF / Share Free cash flow per share
$0.32
↑ +133.3% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —

Health Breakdown

Profitability ↑
38
Returns ↑
72
Financial Health ↓
98
Cash Quality ↓
76

Dividend History

Dividend / share · sourced from SEC filings
$0.18 Latest / share
+12.1% YoY
+57.6% 5-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 65 quarters